Fshd / opmd / myotonic dystrophy

Myotonic dystrophy type 1 (DM1) is characterized by structural changes affecting skeletal muscle tissue, resulting in progressive muscle dysfunction and wasting. Quantitative biomarkers are needed to monitor disease progression and to assess treatment efficacy of upcoming innovative therapeutics. Magnetic resonance imaging (MRI) can provide useful insight for biomarkers since intramuscular fat fraction (FF), as measured by Dixon and water T2 (T2H2O) are considered efficient biomarkers of disease severity and disease activity of various neuromuscular diseases (NMDs) respectively.

Source: Neuromuscular Disorders - September 28, 2020 Category: Neurology Authors: B. Marty, J. Le Lou ër, A. Canal, J. Hogrel, M. Gyenge, N. Jebrouni, H. Reyngoudt, G. Bassez Source Type: research